Tag: Relapsing ms

According to 10-year clinical trial data, 77% of patients with relapsing multiple sclerosis (RMS) treated continuously with Ocrevus were free from disability progression. This article explores the multifaceted question of what is the success rate of Ocrevus infusion by examining clinical trial results and real-world evidence for both relapsing and primary progressive forms of multiple sclerosis (MS).

Clinical trials show that Ocrevus can begin to reduce disability progression within about 12 weeks, though the full effects may take at least 6 months to become apparent. This raises the common question: **How long does it take for Ocrevus to work?**

An estimated 2.8 million people live with multiple sclerosis (MS) worldwide, a condition where the immune system attacks the central nervous system [1.9.1]. For many, a key question is **what is the drug Aubagio used for?** Aubagio is a prescription oral medication used to treat relapsing forms of MS in adults [1.2.1, 1.2.4].